Among men with nonmetastatic castration-resistant prostate cancer, those who were treated with darolutamide had a 59% decreased risk of metastasis compared with placebo recipients.
After an additional 1 year of follow-up, apalutamide plus ADT continued to show a significant decrease in the risk of progression to metastasis or death.
The study is the first to show that treatment with abiraterone acetate/enzalutamide is associated with better survival in African American patients with mCRPC compared with Caucasians.
By targeting prostate-specific membrane antigen, a molecule radiolabeled with lutetium-177 is expected to deliver high doses of beta radiation to distant metastases.
The Decipher genomic classifier predicted metastases and prostate cancer-specific mortality following radical prostatectomy with greater precision in African-American men.
Patients with metastatic CRPC and bone metastases treated with abiraterone plus prednisone/prednisolone had a higher risk of bone fractures when receiving concomitant radium-223.
A high percentage of men with prostate cancer have 1 or more potentially pathogenic germline variants, but would not be eligible for mutation testing under current NCCN guidelines.
In a Spanish study, the highest vs lowest tertile of dietary zinc intake was associated with a significant 66% increased relative risk of low-grade prostate cancer.
Time interval free of biochemical failure may be a potential surrogate end point in the setting of androgen-deprivation therapy evaluation in men with prostate cancer.
In a recently published study, external beam radiation therapy for localized prostate cancer was associated with a 35% increased risk of bladder cancer compared with radical prostatectomy.
Men treated with radical prostatectomy plus radiotherapy for locally or regionally advanced prostate cancer had improved survival but worse adverse events.
Differences in TMB between African and European patients show that “racial mutational disparity is not a technical or computational artifact,” according to authors.
